MetaCap

Emergent BioSolutions (EBS) vs Galectin Therapeutics (GALT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Emergent BioSolutions (EBS) has outperformed Galectin Therapeutics (GALT) over the past year, losing 49.7% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -88.6% for EBS. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $259.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EBS-49.70%GALT-49.72%
+43%-11%-66%
Nov 21, 20251 yearNov 20, 2026
EBS-87.40%GALT0.00%
+144%+18%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EBS versus GALT key metrics
MetricEBSGALT
Share price$5.05$2.69
Market cap$259.65M$271.35M
1-day change-1.94%-4.27%
YTD return-59.14%-35.34%
1-year return-49.70%-49.72%
5-year return-88.58%+4.67%
Forward P/E4.83—
EPS (TTM)$-5.00$-0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$742.90M—
Revenue growth (YoY)-28.81%—
Net income (latest FY)$52.60M$-30.84M
Gross margin56.09%—
Operating margin13.47%—
Net margin7.08%—
52-week high$14.06$7.13
52-week low$4.36$2.03
Distance from 52-week high-64.08%-62.27%
Analyst consensusnonestrong_buy
Avg. price target upside+98.02%+308.92%
Average volume1.11M252.31K
Shares outstanding51.42M100.88M
Employees9009
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Emergent BioSolutions

EBS stock →

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

EBS vs GALT FAQ

Which is bigger, Emergent BioSolutions or Galectin Therapeutics?

Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $259.65M for Emergent BioSolutions (EBS).

Which stock has performed better over the past year, EBS or GALT?

EBS returned -49.70% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.

Are Emergent BioSolutions and Galectin Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons